{"meshTagsMajor":["Molecular Targeted Therapy"],"meshTags":["Leukemia, Myeloid, Acute","Benzimidazoles","Pyrazines","Proto-Oncogene Proteins c-bcl-2","Benzothiazoles","Mutation","Molecular Targeted Therapy","Phenylurea Compounds","Epigenesis, Genetic","fms-Like Tyrosine Kinase 3","Antineoplastic Agents","Isocitrate Dehydrogenase","Humans","Aniline Compounds","Piperidines","Clinical Trials as Topic"],"meshMinor":["Leukemia, Myeloid, Acute","Benzimidazoles","Pyrazines","Proto-Oncogene Proteins c-bcl-2","Benzothiazoles","Mutation","Phenylurea Compounds","Epigenesis, Genetic","fms-Like Tyrosine Kinase 3","Antineoplastic Agents","Isocitrate Dehydrogenase","Humans","Aniline Compounds","Piperidines","Clinical Trials as Topic"],"genes":["FLT3","isocitrate dehydrogenase"],"publicationTypes":["Journal Article","Review"],"abstract":"The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets. ","title":"Molecularly targeted therapies for acute myeloid leukemia.","pubmedId":"26637775"}